Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 17/20 | 0.80 |
| ▸ | ITGA5 | P08648 | 15/20 | 0.80 |
| ▸ | ITGAV | P06756 | 10/20 | 0.80 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.80 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.53 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927387 | 0.94 | ITGB1 (0.72) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL4245995 | 0.91 | ITGB1 (0.67) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL14270764 | 0.88 | ITGAV (0.62) | ITGB1ITGA5ITGAVITGB3ITGB6 | |
| SCHEMBL4067561 | 0.87 | ITGB1 (0.68) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL4071803 | 0.85 | ITGB1 (0.59) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL4929579 | 0.84 | ITGB1 (0.90) | ITGB1ITGA5ITGAVITGB3 | |
| SCHEMBL4066315 | 0.84 | ITGB1 (0.90) | ITGB1ITGA5ITGAVITGB3 | |
| SCHEMBL4064955 | 0.82 | ITGB1 (0.61) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL4201436 | 0.82 | ITGB1 (0.87) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL4253578 | 0.81 | ITGB1 (0.89) | ITGB1ITGA5ITGAVITGB3ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | claimed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | ITGB1 2/4885ITGA5 7/4885ITGAV 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.